Search

Your search keyword '"Boddy, Alan V"' showing total 12 results
Start Over Author "Boddy, Alan V" Journal clinical cancer research
12 results on '"Boddy, Alan V"'

1. A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Author

Moreno, Lucas, primary, Marshall, Lynley V., additional, Pearson, Andrew D.J., additional, Morland, Bruce, additional, Elliott, Martin, additional, Campbell-Hewson, Quentin, additional, Makin, Guy, additional, Halford, Sarah E.R., additional, Acton, Gary, additional, Ross, Philip, additional, Kazmi-Stokes, Shamim, additional, Lock, Victoria, additional, Rodriguez, Ana, additional, Lyons, John F., additional, Boddy, Alan V., additional, Griffin, Melanie J., additional, Yule, Murray, additional, and Hargrave, Darren, additional

Published
2015
Full Text
View/download PDF

3. Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

Author

Plummer, Ruth, primary, Vidal, Laura, additional, Griffin, Melanie, additional, Lesley, Mark, additional, de Bono, Johann, additional, Coulthard, Sally, additional, Sludden, Julieann, additional, Siu, Lillian L., additional, Chen, Eric X., additional, Oza, Amit M., additional, Reid, Gregory K., additional, McLeod, A. Robert, additional, Besterman, Jeffrey M., additional, Lee, Chooi, additional, Judson, Ian, additional, Calvert, Hilary, additional, and Boddy, Alan V., additional

Published
2009
Full Text
View/download PDF

4. Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Author

Daniel, Rachel A., primary, Rozanska, Agata L., additional, Thomas, Huw D., additional, Mulligan, Evan A., additional, Drew, Yvette, additional, Castelbuono, Deborah J., additional, Hostomsky, Zdenek, additional, Plummer, E. Ruth, additional, Boddy, Alan V., additional, Tweddle, Deborah A., additional, Curtin, Nicola J., additional, and Clifford, Steven C., additional

Published
2009
Full Text
View/download PDF

6. Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

Author

Joerger, Markus, primary, Huitema, Alwin D.R., additional, Richel, Dick J., additional, Dittrich, Christian, additional, Pavlidis, Nikolas, additional, Briasoulis, Evangelos, additional, Vermorken, Jan B., additional, Strocchi, Elena, additional, Martoni, Andrea, additional, Sorio, Roberto, additional, Sleeboom, Henk P., additional, Izquierdo, Miguel A., additional, Jodrell, Duncan I., additional, Calvert, Hilary, additional, Boddy, Alan V., additional, Hollema, Harry, additional, Féty, Regine, additional, Van der Vijgh, Wjf J.F., additional, Hempel, Georg, additional, Chatelut, Etienne, additional, Karlsson, Mats, additional, Wilkins, Justin, additional, Tranchand, Brigitte, additional, Schrijvers, Ad H.G.J., additional, Twelves, Christian, additional, Beijnen, Jos H., additional, and Schellens, Jan H.M., additional

Published
2007
Full Text
View/download PDF

8. NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism

Author

Jamieson, David, primary, Wilson, Kerrie, additional, Pridgeon, Simon, additional, Margetts, Jane P., additional, Edmondson, Richard J., additional, Leung, Hing Y., additional, Knox, Richard, additional, and Boddy, Alan V., additional

Published
2007
Full Text
View/download PDF

10. Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

Author

Plummer, E. Ruth, primary, Middleton, Mark R., additional, Jones, Christopher, additional, Olsen, Anna, additional, Hickson, Ian, additional, McHugh, Peter, additional, Margison, Geoffrey P., additional, McGown, Gail, additional, Thorncroft, Mary, additional, Watson, Amanda J., additional, Boddy, Alan V., additional, Calvert, A. Hilary, additional, Harris, Adrian L., additional, Newell, David R., additional, and Curtin, Nicola J., additional

Published
2005
Full Text
View/download PDF

12. Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma

Author

Gareth J. Veal, Nicola A. Illingworth, Julie Errington, Ghada Malik, Michael Cole, Andrew D.J. Pearson, Sophie E. Rowbotham, Alan V. Boddy, Ann K. Daly, Veal, Gareth J, Errington, Julie, Rowbotham, Sophie E, Illingworth, Nicola A, Malik, Ghada, Cole, Michael, Daly, Ann K, Pearson, Andrew DJ, and Boddy, Alan V

Subjects
Cancer Research, medicine.medical_specialty, Population, Retinoic acid, Pharmacology, Body weight, neuroblastoma, chemistry.chemical_compound, Pharmacokinetics, Neuroblastoma, medicine, childhood cancer, Dosing, CYP2C8 polymorphisms, education, Isotretinoin, 13-cis-retinoic acid, education.field_of_study, business.industry, medicine.disease, randomised trial, adaptive dosing, Surgery, Oncology, chemistry, business, pharmacokinetics, Pharmacogenetics, medicine.drug
Abstract

Purpose: To investigate the feasibility of adaptive dosing and the impact of pharmacogenetic variation on 13-cis-retinoic acid (13-cisRA) disposition in high-risk patients with neuroblastoma. Experimental Design: 13-cisRA (160 mg/m2 or 5.33 mg/kg/d) was administered to 103 patients ages 21 years or less and plasma concentrations of 13-cisRA and 4-oxo-13-cisRA quantitated on day 14 of treatment. Seventy-one patients were recruited to a dose adjustment group, targeting a 13-cisRA Cmax of 2 μmol/L, with dose increases of 25% to 50% implemented for patients with Cmax values less than 2 μmol/L. A population pharmacokinetic model was applied and polymorphisms in relevant cytochrome P450 genes analyzed. Results: 13-cisRA Cmax values ranged from 0.42 to 11.2 μmol/L, with 34 of 103 (33%) patients failing to achieve a Cmax more than 2 μmol/L. Dose increases carried out in 20 patients in the dose adjustment study group led to concentrations more than 2 μmol/L in 18 patients (90%). Eight of 11 (73%) patients less than 12 kg, receiving a dose of 5.33 mg/kg, failed to achieve a Cmax of 2 μmol/L or more. Significantly, lower Cmax values were observed for patients treated with 5.33 mg/kg versus 160 mg/m2 (1.9 ± 1.2 vs. 3.1 ± 2.0 μmol/L; mean ± SD; P = 0.023). Cmax was higher in patients who swallowed 13-cisRA capsules as compared with receiving the drug extracted from capsules (4.0 ± 2.2 vs. 2.6 ± 1.8 μmol/L; P = 0.0012). The target Cmax was achieved by 93% (25/27) versus 55% (42/76) of patients in these 2 groups, respectively. No clear relationships were found between genetic variants and 13-cisRA pharmacokinetic parameters. Conclusions: Dosing regimen and method of administration have a marked influence on 13-cisRA plasma concentrations. Body weight–based dosing should not be implemented for children less than 12 kg and pharmacologic data support higher doses for children unable to swallow 13-cisRA capsules. Clin Cancer Res; 19(2); 469–79. ©2012 AACR.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results